Inventor
ZHANG HANCHENG
CN12 patents
⚠️ This page may combine multiple inventors who share the name “ZHANG HANCHENG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HANGZHOU INNOGATE PHARMA CO LTD
11 patentsUS11352353B2Jun 7, 2022
Heterocyclic compound serving as FGFR4 inhibitor
HANGZHOU INNOGATE PHARMA CO LTD2 citations71
US12358911B2Jul 15, 2025
Heterocyclic comipound as CDK-HDAC dual pathway inhibitor
HANGZHOU INNOGATE PHARMA CO LTD0 citations60
US11225492B2Jan 18, 2022
Heterocycles useful as anti-cancer agents
HANGZHOU INNOGATE PHARMA CO LTD1 citations60
US10968234B2Apr 6, 2021
Compound containing tricyclic heteroaryl group
HANGZHOU INNOGATE PHARMA CO LTD0 citations60
US10730887B2Aug 4, 2020
Compound containing tricyclic heteroaryl group
HANGZHOU INNOGATE PHARMA CO LTD1 citations60
US12415797B2Sep 16, 2025
Heterocyclic compound as CDK-HDAC double-channel inhibitor
HANGZHOU INNOGATE PHARMA CO LTD0 citations50
US11142535B2Oct 12, 2021
Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor
HANGZHOU INNOGATE PHARMA CO LTD0 citations50
US10934311B2Mar 2, 2021
Heterocyclic compound used as FGFR inhibitor
HANGZHOU INNOGATE PHARMA CO LTD0 citations50
US11266640B2Mar 8, 2022
Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
HANGZHOU INNOGATE PHARMA CO LTD0 citations49
US12589092B2Mar 31, 2026
Polycyclic compound acting as kinase inhibitor
HANGZHOU INNOGATE PHARMA CO LTD0 citations45
US10358451B2Jul 23, 2019
Heterocycles useful as IDO and TDO inhibitors
HANGZHOU INNOGATE PHARMA CO LTD0 citations39